Obtenga las últimas noticias sobre las acciones de Shattuck Labs con actualizaciones sobre las tendencias del mercado, las finanzas y el análisis de Benzinga. Manténgase informado sobre el rendimiento de STTK

Últimas noticias sobre

SHATTUCK LABS INC

Shattuck Labs

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

Levi Strauss

News

Pre-Market Outlook

Markets

Movers

AREB

BJDX

CHSN

CVRX

GLXG

GRFX

IPDN

IVDA

KNOP

KPTI

LEVI

PRSU

SOBR

STTK

SVRE

Levi sorprende al mercado con ganancias trimestrales mejores de lo esperado y una perspectiva 2025 que mantiene sin cambios.

Acciones de Levi Strauss suben un 10%; Aquí están 20 acciones que se mueven en el premercado de EE. UU.

Shattuck Labs Inc

Health Care

Press Releases

Shattuck Labs Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

Shattuck Labs Announces Poster Presentation at Upcoming 2025 Crohn's and Colitis Congress

Shattuck Labs Announces Oral Presentation at Upcoming 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025

Shattuck Labs Announces Positive Data from the Preclinical GLP Toxicology Study of SL-325 at the 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025

Earnings

Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights

Shattuck Labs Announces Participation in Upcoming 24th Annual Needham Virtual Healthcare Conference

Shattuck Labs Reports First Quarter 2025 Financial Results and Recent Business Highlights

Shattuck Labs Announces Participation in Upcoming Leerink Partners Therapeutics Forum: I&I and Metabolism

Shattuck Labs Announces Oversubscribed Private Placement of Up to Approximately $103 Million

Shattuck Labs Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Acrivon Therapeutics, Inc. - Common Stock

Acrivon Therapeutics

ALX Oncology Holdings Inc. - Common Stock

ALX Oncology Holdings

Annovis Bio

Actinium Pharmaceuticals, Inc. (Delaware) Common Stock

Actinium Pharma

Barinthus Biotherapeutics plc - American Depositary Shares

Barinthus Biotherapeutics

Clene

Coeptis Therapeutics Holdings, Inc. - Common Stock

Coeptis Therapeutics

Equillium

FibroGen

Generation Bio

ImmuCell

Century Therapeutics, Inc. - Common Stock

Century Therapeutics

Jasper Therapeutics, Inc. - Class A Common Stock

Jasper Therapeutics

Kalaris Therapeutics, Inc. - Common Stock

Kalaris Therapeutics

Karyopharm Therapeutics Inc. - Common Stock

Karyopharm Therapeutics

Lantern Pharma

MAIA Biotechnology

PDS Biotechnology Corporation - Common Stock

PDS Biotechnology

PepGen

Prelude Therapeutics Incorporated - Common Stock

Prelude Therapeutics

Renovaro

Serina Therapeutics

Senti Biosciences

Tempest Therapeutics, Inc. - Common Stock

Tempest Therapeutics

Unicycive Therapeutics, Inc. - Common Stock

Unicycive Therapeutics

Leerink Partners

Citigroup

BTIG

Comments

Shattuck Labs Noticias bursátiles

Noticias

Últimas noticias sobre

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL